The research of Deutsche Bank is increasing its opinion on the stock. The broker s advice is neutral against selling initially. The target price is revised upwards from CHF 80 to CHF 70. | March 28, 2023
By Cecilia Butini Novartis AG said Monday that a trial evaluating breast-cancer drug Kisqali met its primary endpoint during an interim analysis. The drug is shown to significantly reduce. | March 27, 2023
In his latest research note, analyst Peter Welford confirms his positive recommendation. The broker Jefferies is keeping its Buy rating. The target price is still set at CHF 100. | March 27, 2023
Novartis has launched a new share buyback programme to purchase up to 10% of the pharma company s own shares over the next three years.. | March 13, 2023